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Abstract 
 
Rapid advances in genotyping technology, analytical methods, and the establishment 
of large cohorts for population genetic studies have resulted in a large new body of 
information about the genetic basis of human rheumatoid arthritis (RA).  Improved 
understanding of the root pathogenesis of the disease holds the promise of improved 
diagnostic and prognostic tools based upon this information.  In this review, we 
summarize the nature of new genetic findings in human RA, including susceptibility 
loci and gene-gene and gene-environment interactions, as well as genetic loci 
associated with sub-groups of patients and those associated with response to therapy.  
Possible uses of these data are discussed, such as prediction of disease risk as well as 
personalized therapy and prediction of therapeutic response and risk of adverse 
events.  While these applications are largely not refined to the point of clinical utility 
in RA, it seems likely that multi-parameter datasets including genetic, clinical, and 
biomarker data will be employed in the future care of RA patients. 
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1. Introduction 
 
The previous era of 'blockbuster' drugs is now giving way to an era of stratified 
medicine in most diseases, with the ultimate goal of delivering the right drug to the 
right patient at the right time, a task that represents a key objective of the modern 
translational medicine. To date, only few studies have demonstrated the impact of 
stratified medicine interventions at population level, probably because of the high 
costs of studies using proper stratification and tailored interventions directly 
compared to universal interventions.   
 
Taking Rheumatoid Arthritis (RA) as an archetype disease, it can be treated with a 
broad variety of immunotherapeutic agents, and even though outcomes have 
improved dramatically recently with targeted therapies, few patients are cured and we 
are still from having sufficient knowledge to allow preventive measures in “at risk” 
individuals. In RA, further complexity is brought with duration of disease and history 
of responses to current therapies. Heterogeneity between patients is in fact one of the 
major features of RA, also reflected in its wide range of responses / non-response to 
therapeutic agents. 
 
The past decade has seen astonishing progress in our ability to decipher genetic and 
molecular reasons behind diseases as complex as cancers, obesity, neurodegenerative 
disorders and autoimmune diseases. Equally exciting, the advances in stem cell 
manipulation, cellular reprogramming, tissue engineering, and genome editing have 
offered possible therapeutic solutions to conditions previously considered untreatable. 
Identifying genetic variants of clinical significance remains however very complex 
and far from perfect technically but such progress has been made over the past few 
years that we are now approaching clinical utility.  
 
There are different approaches using detailed knowledge of human genetic variation 
to tailor treatments to patients. One main approach is to tailor drug treatments based 
upon genetic variations that may affect the metabolism of the drug itself 
(pharmacogenomics).  Another aims to choose a drug according to the best chances of 
response to that particular agent (Personalized Medicine). However, it should be 
pointed that this “personalized medicine” approach does not yet allow treatment to be 
tailored to the needs of each individual but rather allows patients to be stratified into 
groups with a better chance to respond to a particular drug before treatment is started.  
 
In this review, we will use the example of RA to discuss many factors shaping the 
future use of genetic information in personalized medicine, ranging from the 
discovery of RA-associated variants to the resulting insights into disease biology and 
the potential for clinical applications of such findings. 
 
2. The rapidly changing technologies enable new approaches 
 
The history of modern human genetics research is largely the history of the rapidly 
changing technologies.  Although the vast size of the human genome appeared at first 
impossible to work with, the development of new analytical approaches has allowed 
us to reach the point where individual genome sequencing is a feasible task for many 
laboratories (Kere 2010). The sequencing of the human genome represents a critical 
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milestone in the scientific landscape and a springboard for genetic studies 
(International Human Genome Sequencing Consortium. 2001).  
 
The most crucial argument for seeking genetic data is the high heritability of many 
important medical conditions. The extraordinary technical advances in the field of 
human molecular genetics over the past few years have led to an explosion of new 
information about the genetics of complex, multigenic human diseases, notably 
including autoimmune disorders. The design of genetic studies has relied of three 
main components: availability of population (with well defined ethnic/racial groups 
for original and replication studies), technology (with comprehensive coverage of the 
entire genome) and data (as comprehensive as possible) to be associated with the 
outcome of interest. Advances in DNA sequencing and genotyping technology have 
put us in a unique position to consider issues raised by the use of genetics data in 
personalized medicine.  
 
2.1. Genome-wide association studies (GWAS) 
 
During the last decade, many breakthroughs have contributed to the unraveling of the 
genetic etiology and pathophysiology of complex autoimmune diseases and other 
genetic disorders. GWAS have uncovered thousands of variants involved in the 
pathogenesis of many complex human disorders and have proven a powerful 
hypothesis-free method to identify common disease-associated variants. This method 
identifies SNPs that are present in the general population, but it cannot predict 
functional consequences. Such genetic associations identify a region or genetic locus 
that is associated with disease, but the specific causative mutation within that locus is 
not immediately identified.   
 
Despite the success of GWAS, a substantial heritability gap remains.  GWAS have 
identified a high number of loci common to several autoimmune diseases, such 
variants despite being common have a modest-effect size and thus a substantial 
fraction of heritability remains unexplained and/or hidden (Manolio et al., 2009).  
Some of this missing heritability should be accounted for by low-frequency and rare 
variants, which would be expected to have large biological consequences (Zeggini 
2011).  Rare variants can be discovered by re-sequencing a small sample size cohort 
and then genotype the discovered variants in a larger sample set (Rivas et al., 2011; 
Momozawa et al., 2011). The study of these rare variants can be strengthened by 
focusing on isolated or well-defined populations, where an appropriate combination 
of data from whole genome sequencing and GWAS as well as imputation of variants 
into a reasonable study may lead to the detection of susceptibility loci for complex 
diseases (1000 Genomes Project Consortium et al., 2010; Holm et al., 2011).  GWAS 
have not yet reached their limits and although the majority of GWAS that have 
discovered common variants for human diseases were performed using a case-control 
design, an interest has been expressed in using family-based designs for GWAS. The 
reason for this new tendency caused by the expansion of new generation sequencing 
(NGS) methodology, which outlined the importance of the rare variants in disease 
susceptibility (Ionita-Laza and Ottman, 2011).  Also, the use of GWAS to study 
patient subgroups, comparing patients with different subtypes of a disease has been 
fruitful recently (Kariuki 2015). 
 
2.2. Allelic discrimination by Taqman Real Time PCR 
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Real-time PCR is a very popular procedure for the quantification of gene expression 
(Ponchel et al., 2003). This technique monitors the progress of a PCR reaction as it 
develops to quantify a relatively small amount of initial sequence (DNA, cDNA or 
RNA). Quantification is based on the detection of the fluorescence produced by a 
reporter molecule, which increases as the reaction proceeds. These fluorescent 
reporter molecules include dyes that bind to the double-stranded DNA (i.e. SYBR® 
Green) or sequence specific probes (i.e. Molecular Beacons or TaqMan® Probes) 
(Bustin 2000). An important application of the TaqMan PCR is the detection of 
known gene mutations or polymorphisms. This is based on the design of two TaqMan 
probes, each specific for one allele (A or B) representing the 2 alternative sequences. 
Both probes are labeled with two different fluorescent tags. The TaqMan probe is then 
designed to bind the gene sequence flanking the mutation (Livak et al., 1995). 
TaqMan probe-based assays are widely used in research and medical laboratories for 
the purposes of SNP genotyping and Pharmacogenomics.  
 
2.3. Sequencing - Next Generation Sequencing (NGS) 
 
DNA sequencing and genotyping technologies have advanced quickly over the past 
decade, with the development of novel methodologies and machinery and the 
utilization of new types of molecular tools. The first DNA sequencing technologies 
were the product of academic research in the 1970s, with the near simultaneous 
development of two methods based on the electrophoretic separation of a nested set of 
labeled DNA products.  The first one was developed by Allan Maxam and Walter 
Gilbert while the second one, developed by Frederick Sanger, is the basis of today’s 
high-throughput DNA sequencing. The second major advance in DNA sequencing in 
the 1980s was the development of automated DNA sequencing instruments, 
introducing base-specific fluorescent dyes and capillary electrophoresis into the 
process. More recently “next-generation DNA sequencing (NGS) technologies” are 
summarized in Table 1.  
 
The use of NGS technologies has assisted in the identification of common and rare 
variants determining the response to drugs or serious adverse drug reactions 
(Wadelius et al., 2009; Carr et al., 2014). Personal genome sequencing is becoming a 
reality, and targeting whole exome sequencing is being explored to facilitate diagnosis 
and guide treatment in some conditions, mainly regarding monogenic diseases such as 
primary congenital glaucoma, Wolfram syndrome, and many others(McLaughlin et al 
2014). Recently, guidelines were developed representing initial steps to ensure that 
results from tests based on NGS are reliable and useful for clinical decision making 
(http://www.cdc.gov/osels/lspppo/Genetic_ Testing_Quality_Practices/Nex-
StoCT.html).  
 
2.4. Exome Sequencing 
 
Sequencing the coding regions, the exome of the human genome, is one of the major 
current strategies to identify rare, low frequency variants as well as de novo mutations 
that are associated with human diseases. Sequencing the entire protein-coding 
sequence is one of the major applications of NGS. The GENCODE consortium 
(Coffey et al., 2011) notably designed an extended set of primers to capture the 
complete human genome, covering an additional fragment of 10.3 Mb harboring 5594 
more genes compared with the widely used commercial kit from the consensus coding 
sequence consortium (CCDS) database-base (Pruitt et al., 2009). These additional 
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regions include potential disease genes, which were previously inaccessible, thus 
resulting in the identification of over 5000 new SNP variants. Exome strategies are 
believed to be more potent towards the identification of Mendelian disease genes, and 
this method is a commonly used tool to identify causal variants in these diseases 
(Gilissen et al,. 2013).  
 
2.5. Expression quantitative trait loci (eQTLs) 
 
Gene expression is differentially regulated across tissues, and many human transcripts 
are expressed in a limited set of cell types or during particular stages of a disease. The 
abundance of a gene transcript can be directly modified by polymorphisms in 
regulatory elements. Consequently, transcript abundance might be considered as a 
quantitative trait that can be mapped with considerable power. Expression quantitative 
trait loci (eQTLs) are genomic loci that regulate expression levels of mRNAs or 
proteins (Consoli et al., 2002). Importantly, expression traits differ from most other 
classical complex profile in one important respect—the measured mRNA or protein is 
the product of a single gene with a specific chromosomal location. Studies have 
shown that SNPs reproducibly associated with complex disorders (Nicolae et al., 
2010) as well as certain pharmacologic phenotypes (Gamazon et al., 2010) are 
significantly enriched for eQTLs, and high-throughput measurement of genome-wide 
transcription using microarray technology has greatly facilitated the systematic 
mapping of eQTLs. Considering that genes mediate their biological roles in groups 
rather than in isolation, an interesting challenge will be the extension of the concept of 
eQTLs to whole genome pathway analysis.  
 
2.6. Epigenetics and Epigenome-Wide Association Studies (EWAS) 
 
DNA sequences carry genetic information within a dynamic complex of chromatin 
and regulatory sequences, such as transcription factors binding sites, which control 
the readout of the DNA sequence (Kilpinen and Dermitzakis 2012). A higher 
hierarchy also exists at the chromatin levels, with an overall backbone defined as the 
epigenome, consisting of nucleosomes that are made up of wrapped DNA around 
histone proteins. The functional importance of epigenetic changes lies in their ability 
to regulate gene expression. Recent technological advances have allowed the 
detection of a plethora of histone modifications and related chromatin structures 
(methylation, acetylation, and ubiquitination) (Zhou et al., 2011). DNA methylation 
markers may be useful as diagnostic and prognostic markers in many human diseases 
(Rakyan et al., 2011). Thus, the genome gives information about sequence and 
structure, whilethe epigenome provides information regarding genome function 
(Verma 2012). 
 
Epigenetic mechanisms contribute to many fundamental biological processes and to 
the pathogenesis of complex human diseases.  For example, epigenetics may help to 
explain individual variation in drug responses, thus representing important potential in 
personalised medicine (Feinberg 2010). Epigenome-wide association studies (EWAS) 
provide an opportunity to identify genome-wide epigenetic variants that are associated 
with disease. EWAS offer a potential to increase our understanding of complex 
disease, but also pose some challenges that are not encountered in GWAS, such as the 
fact that epigenetic changes can vary over time in relation to disease course and 
medication use. Interestingly, Rakyan et al (2011) suggested a way that an integration 
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of EWAS with GWAS could help to dissect complex GWAS haplotypes for further 
functional analysis.   
 
3. Genetics of Rheumatoid Arthritis 
 
3.1. Genetic risk factors 
 
Rheumatoid Arthritis is a chronic, progressive systemic inflammatory disease, 
affecting approximately 0.5–1 % of the population (Alamanos and Drosos 2005), that 
if uncontrolled may lead to significant joint damage, pain, dysfunction, work 
disability that results in large economic losses. Although genetic influences on 
susceptibility to and clinical course of RA have been known for a long time, only 
recently have they been approached systematically through the advances in 
genotyping technology and GWAS. Findings from elegant twin studies (Silman et al., 
1993; MacGregor et al., 2000) have estimated the heritability of RA at about 50-60%, 
thus suggesting the remarkable influence of genetic factors on disease susceptibility, 
while the remaining part can be attributed to environmental factors or chance. 
 
Before the GWAS era, RA susceptibility loci were detected using the traditional 
candidate-gene approach and linkage analysis, discovering the two most significant 
RA risk loci, HLA-DRB1 that exhibits the largest genetic contribution to RA 
susceptibility, and the group of alleles referred to as the shared epitope (SE) 
(Welcome Trust Case–Control Consortium 2007). The PTPN22 (Bottini et al., 2004), 
PADI4 (Suzuki et al., 2003) and CTLA‑4 genes (Plenge et al., 2005) were also 
identified as risk factors in the pre-GWAS era prior to 2007. In the next few years, 
many more RA-susceptibility genes were discovered using GWAS study designs, 
which thus far have identified over 110 susceptibility loci for RA in European and 
Asian populations (Eyre et al., 2012; Orozco et al., 2014).  Somewhat surprisingly, 
these susceptibility loci account for less than 50% of the total genetic heritability 
(Okada et al., 2014), suggesting that there is a significant portion of the genetic 
architecture of RA that remains to be discovered. Many of these loci associated with 
risk for RA are lying in one main biological pathway related to T-cell activation and 
signaling (HLA–DRB1, PTPN22, PTPN2, STAT4, CD40, CTLA4, IL2, IL21, IL-6R, 
GATA3, CCR6, IL-2R, IL-7R, CD28) (Plenge et al., 2007; Martinez et al., 2008; 
Raychaudhuri et al., 2008; Barton et al., 2009; Orozco et al., 2009; Cobb et al., 2013). 
 
Following the GWAS era, an important development was the use of a novel 
genotyping array called Immunochip. The Immunochip was a custom Illumina 
Infinium genotyping array designed by the Immunochip Consortium to include risk 
loci confirmed in 12 major autoimmune diseases (Cortes and Brown 2011), mapping 
in total 196,524 SNPs of which ~3,000 were specific for each disease and including 
dense coverage of the extended HLA region and 186 non-HLA risk loci.  Considering 
that a remarkable number of loci associated with RA susceptibility were also 
associated with multiple other autoimmune diseases (Hinks et al., 2005; Behrens et 
al., 2008; Zervou et al., 2008; Zhernakova et al., 2009; Kurreeman et al., 2010), it was 
thought that the mapping of loci discovered in other diseases might establish the same 
loci as RA-risk loci.  Additionally, the fine-mapping nature of the chip would be 
important to understand how individual variants contribute to risk of disease. Use of 
the platform in RA allowed the detection of novel RA-associated loci such as BACH2 
and RAD51B.  
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The small odds ratios for the majority of these risk factors make these findings of 
limited importance with regard to their potential use in the prediction of the risk for 
the disease for individual patient. The current challenge is to translate this genetic 
information into concrete mechanism of how these variants interact with each other or 
with environmental factors in order to lead to RA (Gregersen and Olsson 2009).  
 
Joint destruction is an accurate measure for RA severity and reflective of the 
cumulative disease burden. Therefore, risk factors for this outcome measure may be 
used to arrive at individualized treatment strategies (van der Helm-van Mil et al., 
2010). It has been shown that genetic variants of IL-15 (Knevel et al 2012), IL4R 
(Krabben et al., 2013), IL2RA (Knevel et al., 2013a), GZMB (Knevel et al., 2013b), 
Dkk-1 (de Rooy et al., 2013), MMP-9 (de Rooy et al., 2014), MMP-3 (Knevel et al., 
2014a), OPG (Knevel et al., 2014b), PTGER4 (Rodriguez-Rodriguez et al., 2015), 
TRAF1/C5 (van Steenbergen et al., 2015) as well as the rs2833522 SNP (De Rooy et 
al., 2013) are associated with RA severity as reflected by radiological damage and 
joint destruction appeared in RA patients. Moreover, it has been reported that RA 
patients with the Blimp-1 risk allele show more synovial inflammation than those 
without this allele (Herenius et al., 2011). 
 
3.2. Role of genetic factors in the context of ACPA+ and ACPA -   
 
During recent years, it has become clear that RA is composed of several phenotypes 
with defined and different genetic and environmental risk factors. One of such major 
phenotyping criteria is the presence/absence of anti–citrullinated peptide antibodies 
(ACPAs) despite continuing debate as to whether ACPA positive and negative RA 
represent two different subsets of the same disease or are two distinct diseases 
altogether (van der Helm-van Mil and Huizinga 2008; Daha and Toes 2011). Indeed, 
there are clearly significant differences in risk allele frequency that are mainly 
associated with loci in the HLA region supporting the distinct genetic etiologies 
hypothesis for ACPA+ and ACPA- RA (Padyukov et al., 2011). The presence of these 
antibodies is associated with HLA–DRB1 shared epitope (SE) alleles (Klareskog et al., 
2006). ACPA positivity has been associated with more progressive, more destructive 
RA and extraarticular manifestations as well as cardiovascular disease (Visser et al., 
2010). Importantly, it was shown that a non-SE HLA–DRB1 allele (HLA–DRB1*15) 
is associated with production of high levels of ACPAs in RA patients, suggesting a 
role for this genetic background in adaptive immunity (Laki et al., 2012).  
 
Numerous genetic studies have now been conducted in RA patients stratified as either 
ACPA positive or negative. Genetic associations appear stronger in general in the 
ACPA+ subgroup (Huizinga et al., 2005; de Vries et al., 2011). Some loci, such as 
CD2/CD58, AFF3, CD28, CTLA-4, PXK, RBPJ, TAGAP, CCR6, IRF5, TRAF1/C5, 
CD40.  HLA–DRB1*15, HLA–DRB1*03, BACH2, RAD51B, AFF3 locus 1, CCR6, 
CCL21 locus 2, IL2RA locus 2, CD28, CD40, PXK, REL, RBPJ, TNFRSF14, 
TNFAIP3 locus 3, HLA-DRB1*01, HLA-DRB1*04, HLA-DRB1*15, associated with 
ACPA+ RA were not associated with ACPA- disease (Verpoort et al., 2005; Thabet et 
al., 2009; Padyukov et al., 2010; Kurreeman et al., 2011; Daha et al., 2012; Laki et al., 
2012; Kurko et al., 2013; McAllister et al., 2013; de Rooy et al., 2015) while others, 
such as TNFAIP3, STAT4, BLK, PTPN22, ANKRD55/IL6ST and GIN1/C5orf30, were 
found to be associated with susceptibility for RA irrespective of the serological status 
of the patients (Pierer et al., 2006; Viatte et al., 2012). In addition, IRF5, HLA-
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DRB1*03 and HLA-DRB1*13 were found to be associated with susceptibility for 
ACPA- RA only (Padyukov et al., 2010, Kurko et al., 2013). Together, the number 
and identity of the risk loci associated with the two disease serotypes are different, 
thus strengthening the concept that they might be two genetically different diseases 
(Viatte et al 2012). 
 
ACPAs are considered to be strong predictors of disease activity and radiological 
damage (Bukhari et al., 2007). Positivity for ACPAs is considered to be an important 
biomarker for the classification of RA patients in two subgroups (Klareskog et al 
2009), considering that ACPA positivity is associated with worse response to anti–
tumor necrosis factor therapy (Potter et al., 2009). However, despite genetic 
differences and/or similarities established between ACPA positive and negative RA 
and serotypes showing significant differences in disease severity and course, ACPAs 
are not currently used to guide treatment decision in clinical practice (Viatte et al 
2012).  
 
3.3. Gene-Gene interactions 
 
Gene x Gene interaction (GxG) refers to the situation in which the effect of one 
genotype is conditional on genotypes at one or more other unlinked loci. Interactions 
occur when the effect of one factor upon phenotype (i.e. disease), is modulated by 
other factors. The current debate over the source of genetic variation in disease may 
therefore move from ‘is it caused by (rare or common) variants?’ or even from ‘how 
much does each variant contribute?’ to rather ‘how do they work together?’ (Schork 
et al., 2009). The models above which calculate the amount of heritability accounted 
for by the known genetic variants in RA generally do not account for GxG 
interactions. 
 
Multiple gene interactions have been reported in RA so far but only the HLA-DRB1 
(SE) × PTPN22 interaction has been replicated convincingly, which leads to the 
development of ACPA+ RA. HLA-DRB1 and PTPN22 genetic polymorphisms were 
previously shown to be associated with an increased risk for ACPA+ but not ACPA- 
RA. Thus, a study conducted by Kallberg et al. (2007) showed that in RA, the R620W 
polymorphism of PTPN22, which alone provides a moderate effect, can exert much 
more significant effects in combination with the HLA-DRB1 SE alleles that account 
for approximately one-third of the genetically determined susceptibility to the disease 
(Wordsworth et al., 1992). The fact that the PTPN22 risk (T) allele appears to 
contribute a risk mainly when HLA- DRB1 SE alleles are present, provides strong 
evidence that MHC class II–dependent T-cell activation is of central pathogenetic 
importance for the subset of RA characterized by presence of ACPA antibodies 
(Kallberg et al., 2007).  
 
Another interaction was shown between SNPs in the HLA region and a SNP on 
chromosome 1 (rs2476601) (González-Recio 2009), while pairwise epistatic 
interactions were detected between PTPN22 and seven SNPs corresponding to 
CEP72, MYO3A and CDH13 genes (Briggs et al., 2010). In another study, a deletion 
polymorphism in glutathione S-transferase Mu-1 (GSTM1-null) was found to exert 
significant additive interaction with SE on the risk of ACPA positivity in RA (Mikuls 
et al., 2010). A genome-wide epistasis analysis of SNP x SNP combinations identified 
interacting SNP pairs between the SULF1 and 2 SNPs from the AKAP1 gene (Julià et 
al., 2007). In another interaction was shown a high-degree of synergy between IL6 
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and IL4I-1 promoter polymorphisms, leading to the aggressive phenotype of synovial 
fibroblast in the development of RA (Julia et al., 2007). Finally, it was recently shown 
that a CD86 and a CD40LG genotype were interactively related with a significant risk 
of developing RA (Lee et al., 2014). 
 
3.4. Gene-to-Environment interactions 
 
Many factors such as diet, exposure to toxins and microbes, and socioeconomic status 
all profoundly influence health. This information is especially important in 
understanding susceptibility to disease. Gene-to-Environment (G×E) interactions refer 
to the situation in which the effect of the genotype is conditional depending onthe 
environment. It has been long suspected that genetic and environmental factors work 
together to cause RA, and evidence in support of these interactions suggests that there 
may be many pathways to RA.  
 
Many environmental factors have been associated with RA but only smoking has been 
proved to interact with certain genes in RA. A large body of evidence shows the role 
for cigarette smoking in causing RA, although this is now clearly related to the 
presence of a specific genetic background. The first studies conducted in GxE 
interaction in RA showed that the disease risk of Rheumatoid Factor (RF)-
seropositive RA associated with SE was strongly influenced by cigarette smoking 
(Symmons et al., 1997; Karlson et al., 1999). The effect of smoking on increasing the risk 
of RA with respect to intensity and duration or cessation has been studied and results have 
indicated that the risk of developing RA increases in a dose-response manner with the 
intensity (Heliovaara et al 1993) and the duration of smoking (Stolt et al., 2003; Costenbader 
et al., 2006). A recent prospective study highlighted that even light cigarette smoking is 
associated with increased risk of RA in women and that smoking cessation may reduce, 
though not remove, this risk (Di Giuseppe et al., 2013). Furthermore, excessive caffeine 
consumption, oral contraceptive use and having a first-degree relative with schizophrenia 
were found to confer a higher risk to develop ACPA
+
 RA, while moderate alcohol 
consumption has been suggested that might protect against RA (Pedersen et al., 2006). 
Alcohol consumption was shown to reduce the risk of developing ACPA+ RA in smokers 
carrying HLA-DRB1 SE alleles (Källberg et al. 2009). A meta-analysis indicated that 
both smoking and the PTPN22 risk allele (“T”) are associated with the risk of ACPA 
positivity (Taylor et al., 2013). Finally, in a study specifically undertaken to examine 
the impact of smoking and genetic on RA susceptibility, a significant GxE interaction 
was detected between the GSTT1 gene and heavy smoking (Keenan et al., 2010). 
Notably, more recent findings showed that smoking and the interaction between 
smoking and SE is associated with the concurrent presence of all three RA-associated 
autoantibodies, that is rheumatoid factor (RF), ACPA and anti-carbamylated protein 
antibodies (CarP) (Gan et al., 2015). 
 
 
Several microorganisms have been implicated in the development of RA. One 
hypothesis is that these microorganisms trigger the development of RA in individuals 
who carry genetic susceptibility factors to the disease (Tobon et al., 2010); however, 
the role for microorganisms as initiating factors of RA remains controversial. There 
are findings supporting the hypothesis that oral infections play a role in RA 
pathogenesis, while of special importance are the impact of periodontal pathogens, 
such as Porphyromonas gingivalis on citrullination, and the association of 
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Periodonditis (PD) in RA patients with seropositivity toward RF and ACPA (Detert et 
al., 2010). 
 
An association has been suggested in human between RA and exposure to mineral oil 
(Kleinau et al., 1991; Cannon et al., 1993), although it has not yet been possible to 
determine to what extent this risk is restricted to individuals with a certain genetic 
constitution. However, a family study conducted in the UK showed an increased risk 
of RA in individuals carrying a certain allele of a gene on human chromosome 17, 
which is syntenic to the genetic region that determines susceptibility to oil-induced 
arthritis in rats (Klareskog et al. 2002). Another study showed that exposure to 
mineral oil is associated with an increased risk to develop RF+ and ACPA+ RA, 
respectively (Sverdrup et al., 2005). Mineral oils used in the aforementioned study 
varied between motor oil, hydraulic oil, form oil, or asphalt.  
 
4. Pharmacogenetics and Pharmacogenomics: The promise of 
personalized medicine  
 
Humans vary in their responses to drugs, and genetic factors are hypothesized to 
account for 20-95% of this variation (Harper and Topol 2012).  Pharmacogenetics 
refers to inherited differences in the ways patients process drugs, while 
pharmacogenomics encompasses the overall genetic information that can help predict 
drug response. In RA, pharmacogenomics has been used to identify SNPs or multiple 
genetic signatures that may be associated with responses to traditional disease-
modifying drugs (DMARDs) and biologics. These genetic markers could be useful in 
daily practice because they do not vary with time, and analysis can be carried out 
using samples derived from patient’s blood.  
 
In the past decade, advances in pharmacogenetics and pharmacogenomics have 
gradually unveiled the genetic basis of inter-individual differences in drug responses 
(Evans and Relling 1999; 2004). Considering that genes code for protein targeted by 
drugs or enzymes that regulate drug metabolism, the use of pharmacogenomics 
predictions in combination with the development and improvement of 
genetic/diagnostic tests would allow the stratification of patients into genetic 
subgroups, allowing the prescription of drugs only to subjects that are predicted to 
have high drug efficacy without any undesired toxicity or adverse events. Relatively 
few GWAS investigating drug response have been published. Nowadays, the 
application of pharmacogenomic tests is still limited to a relatively small number of 
diseases. The use of a recommended genetic test prior to prescribing a drug can vary 
widely across disciplines but the most immediate applications of pharmacogenomics 
are in the field of cancer where drugs are already targeted to small groups of patients 
and the level of clinical specialization is high. Thus, it is well known the role of 
CYP2D6 in the prediction of response to tamoxifen (Goetz et al 2008) or the 
association of polymorphisms in the metabolic enzymes  P450 (CYP) with drug 
response, toxicity and cancer risk (Bozina et al 2009) .  
 
4.1. Pharmacogenomics in RA 
 
In addition to susceptibility to RA, some genes may have relevance for disease 
outcome and prognosis (Davila and Ranganathan 2011; Plant et al., 2011). To date, 
biologic agents for RA include TNF blockers (infliximab, etanercept, adalimumab, 
13 
 
certolizumab, and golimumab), the B cell-depleting anti-CD20 antibody (rituximab), 
the cytotoxic T-lymphocyte antigen-4 fusion protein (abatacept) that inhibits co-
stimulation, the IL-1 receptor antagonist (anakinra), the IL-6 receptor inhibitor 
(tocilizumab) (Atzeni et al., 2012) and the Janus-associated kinase (Jak) inhibitor 
(tofacitinib), which blocks the cytokine pathway that leads to the activation of 
lymphocytes (Lee et al., 2014). Although existing recommendations do not 
distinguish between ACPA-positive and ACPA-negative RA with regards to the 
choice of biological therapy, there are convincing data to suggest superior efficacy of 
agents such as anti-CD20 mAb and CTLA4.Ig in ACPA-positive patients. SNPs in 
several genes have been associated with altered efficacy or toxicity of methotrexate 
(MTX), such as those in genes such as MTHFR, SLC19A1, SHMT1, ABCB1, IL1RNα 
as well as ATIC and TYMS (Berkun et al., 2004; Dervieux et al., 2004; Tolusso et al., 
2006; Kurko et al., 2013, Salazar et al 2014). Moreover, an association was detected 
between efficacy of MTX and a single SNP within the GGH gene while 5 SNPs 
mapped to DHFR and 2 mapped to FPGS were significantly associated with adverse 
events (Owen et al., 2012). An increased toxicity of azathioprine has been associated 
with SNPs of TMPT and ITPA genes (Stolk et al., 1998). Additionally, it was found 
that mutations in the NAT-2 gene resulted in adverse events in patients with RA taking 
sulfasalazine (Tanaka et al., 2002). SNPs in the DHODH, ESR1 or CYP1A2 genes 
have been associated with increased efficacy of leflunomide, an isoxazole derivative 
used as a DMARD for the treatment of RA (Powlik et al., 2004; Dziedziejko et al., 
2010).  
 
Treatment strategies blocking tumor necrosis factor (anti-TNF) have proven very 
successful in patients with RA, showing beneficial effects in approximately 50-60% 
of the patients only, for reasons that are still unknown. Many studies have been 
conducted recently based either on single SNPs or on more extensive 
pharmacogenomic investigations, aiming to analyze the efficacy of the biological 
agents used (mostly etanercept, infliximab, adalimumab). Such pharmacogenetic 
studies have unraveled genes involved in various signaling pathways that regulate key 
immune and inflammatory processes. Studies that were conducted following a 
candidate-gene approach confirmed a role for several know susceptibility genes  
including HLA-DRB1, PTPRC, PTPN2, AFF3 and CD226 (Criswell et al., 2004; 
Potter et al., 2009; Tan et al., 2009; Cui et al., 2010; Plant et al., 2012). Using GWAS, 
more gene loci have been identified (including PDE3A–SLCO1C1, NUBPL, CNTN5, 
VAV1, SPRED2, PDZD2, EYA4, CENTD1, MAFB2, QK1, LASS6, IFNK, CST5, 
GBP6, PON1, LMO4 and MOBKL2B) (Liu et al., 2008; Plant et al., 2011; Acosta-
Colman et al., 2013; Mirkov et al., 2013). Data of many of these studies are however, 
still highly inconclusive given that different publications have observed different 
associations.  Some of these differences may be attributed to: differences in ethnic 
populations, demographics and disease stages, previous drug history, definition of 
response, and size of cohorts  (Adarichev et al 2005; Davila and Ranganathan 2011; 
Zervou et al., 2013;Burska et al., 2014). 
 
A pharmacogenomic study in a small number of RA patients treated with tocilizumab 
showed differential expression levels for 4 genes, namely DHFR, CCDC32, EPHA 
and TRAV8 between baseline and after 4 weeks of treatment (Kurko et al., 2013) but 
the information about the role of these genes in RA is still poorly understood.  
 
Some TGFβ1 SNPs are associated with a good response to rituximab therapy, and as 
such could be useful genetic biomarkers in predicting therapy outcome (Daien et al., 
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2012). Furthermore, it has been suggested that BAFF gene 871C>T promoter 
polymorphism may be useful in prediction of treatment outcome in RA patients 
treated with rituximab after failure or intolerance to TNF blockers (Ruyssen-Witrand 
et al., 2012a), while genotyping for 158V/F polymorphism of FcGRIIIa may be 
helpful in prediction of rituximab treatment outcome as well (Kastbom et al., 2012; 
Ruyssen-Witrand et al., 2012b) (for details regarding all pharmacogenetics 
information see Table 2). Thus far, none of the above markers has been validated 
sufficiently to allow for use in the clinical prediction of response to rituximab. 
 
4.2. Personalized medicine achievements 
 
The success of personalized medicine is critically dependent on performance 
accuracy, given that the reliability and specificity of any laboratory test limits the 
degree to which it can be used to personalize a treatment. Furthermore, accurate 
patient phenotyping will always remain the most crucial part of studies attempting at 
gaining insights on novel genetic markers for drug safety and efficacy (Gurwitz and 
McLeod 2013). The success of personalized medicine at the level of a single 
individual is dependent on “tailoring” therapy based upon information obtained at a 
group level (population/cohort) and the specific biological, genetic, and clinical 
characteristics of an individual.  Also, other factors need to be considered such as 
ethnicity, differences in life-style, and environmental factors (as well as co-existing 
susceptibility factors for other diseases); as these will bring additional complexity not 
reflected by the genetic make-up of the individual (Gurwitz and Pirmohamed 2010).  
 
In RA, although there is not yet any guidance about which treatment will be the most 
suitable for any particular patient, it seems likely that genetic variation will be useful 
in predicting treatment response. Most likely a multi-parameter approach will be 
employed that utilizes a combination of predictors based on profiling DNA, RNA and 
proteins, with clinical and epidemiological information to establish an appropriate 
clinical decision-making algorithm (Acosta-Colman et al., 2013). To maximize the 
use of genetic information recently gained, it is necessary to obtain matched 
knowledge of the molecular pathogenesis of the different subsets of RA.  
  
Clinical risk assessment for complex disease is currently based on family history, 
lifestyle and shared environmental factors, with a low predictive value (Khoury et al., 
2010; McClellan et al., 2013). The development of assessment tools that will take 
advantage of individual genomic information may have a higher predictive value, 
allowing for translation of recent genetic research findings into clinical practice 
(Green and Guyer 2011).  
 
5. Looking towards the future 
 
The past decade has seen astonishing progress in our ability to decipher genetic and 
molecular factors underlying complex diseases such as RA. Meanwhile, advances in 
the etiology of disease and the ability to manipulate the genome should make it 
possible to personalize the diagnoses and treatment of RA. Developments in 
genomics, including NGS technologies, are expected to enable a more personalized 
approach to clinical care, with improved risk stratification and treatment selection 
based upon detailed knowledge of an individual’s genetic background. 
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Following the discoveries made using GWAS, the promise of NGS technologies are 
the analysis of the whole genome to identify rare variants, which could have larger 
effect sizes (Heinzen et al., 2012). Genome-wide re-sequencing efforts are now under 
way and will provide a more comprehensive description of the relations between 
genome variation and major clinical phenotypes. Despite the large numbers of 
GWASs performed to date in RA, a significant portion of the heritability of the 
disease remains to be explained (Heap and Heel 2008). Many complementary 
strategies have been developed in an attempt to explain this missing heritability. Also, 
larger cohorts of patients (and controls) obtained via international collaborations will 
increase the power of genetic studies and facilitate discovery. The majority of these 
new methods have potential to greatly improve our knowledge of the genetic 
architecture of RA. Exome sequencing has been very useful in rare diseases with 
Mendelian inheritance, and some recent studies using this method in complex 
autoimmune disease have been successful (i.e. in scleroderma, Gao et al., 2016). 
Whilst most of the eQTL studies in RA have been done after a locus has been 
discovered as a risk locus (Okada et al., 2014), there is potential for this method to be 
used earlier on in the discovery process as a screen or filter of likely candidate loci, as 
autoimmune disease risk loci are enriched for eQTLs (Nicolae et al., 2010). In gene 
discovery efforts it seems likely that using extremes of phenotype or stratification by 
immune system phenotypes will also be valuable, and thus far there is precedent that 
completely new loci can be discovered when subphenotypes are examined (Kariuki et 
al., 2015). 
 
By incorporating gene expression as a biological output related to the genetic 
variation, it is possible that eQTL methods could enhance pharmacogenomic efforts in 
RA. Similarly, the dense genotype information provided by NGS could provide 
additional resolution at the genetic level, although with a burden of a larger data set 
and greater difficulty in excluding false positive findings. It seems likely that 
prediction of treatment response and pharmacogenomics in RA will need to 
incorporate many variables to provide clinically useful prediction – including genetic, 
gene expression, protein expression and immune cell parameters, and clinical and 
demographic information.  
 
In the last 5 years, the field of epigenetics has progressed impressively, and the role of 
diverse epigenetic modifications in the development of many diseases including RA 
has been extensively studied. In RA, these modifications notably affect synovial 
fibroblasts, resulting in the development of an aggressive, intrinsically activated 
phenotype (Klein et al., 2012). These studies suggest the possibility of epigenetic 
targeting agents as a potential new treatment for RA (Gray 2013). Linking genetic and 
epigenetic data with gene expression and proteomics/metabolics is certainly the 
biggest challenge we are facing, and novel tools needs to be developed to this end. 
 
It is clear from the above that genetic testing offers great potential for understanding 
the biology of RA as well as for patient management and personalisation of treatment. 
As for any biomarker/therapy/device/test, it takes several years for any product to 
reach clinics, starting from basic research and initial discovery, followed by 
validation, clinical utility, manufacturing of a robust test, and its final approval by 
regulatory authorities. The use of genetic information will not escape this long 
winding road, but work done in the cancer field to link particular genetic variants with 
clinical decisions and outcomes has paved the way for many other diseases to take 
this journey.  
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Name Principle Reference 
Sanger sequencing  enzymatic dideoxy 
DNA sequencing technique based 
on the chain-terminating 
dideoxynucleotide analogues 
Sanger et al., 1977 
Allan Maxam and Walter 
Gilbert sequencing  
chemical degradation 
DNA sequencing technique in 
which terminally labeled 
DNA fragments were 
chemically cleaved at specific 
bases and separated by gel 
electrophoresis 
Maxam and Gilbert 1977 
Automated sequencing  separated fluorescent bands of 
DNA are detected near the 
bottom of a tube, and the 
sequence information is 
acquired directly by computer. 
Smith et al., 1986 
Pyrosequencing  depends on the detection of 
pyrophosphate release on 
nucleotide incorporation  
Ronaghi et al., 1996 
SOLiD   repeated rounds of ligation and 
cleavage of oligonucleotide 
probes to amplify DNA 
fragments in an emulsion PCR 
with small magnetic beads 
Mardis 2008    
combinatorial probe-anchor 
ligation (cPAL)  
 repeated rounds of ligation and 
cleavage of oligonucleotide 
probes 
Drmanac et al., 2009 
GWAS  detects genetic variation 
that is relatively common, e.g., 
genetic variants that have 
frequencies of 5% or more in 
the general population. 
Hardy and Singleton 2009 
single-molecule, real-time 
SMRT  
Ion semiconductor sequencing 
that is based on the detection of 
hydrogen ions released during 
DNA synthesis or to 
Pyrosequencing, a form of 
sequencing by synthesis that 
relies on the detection of 
pyrophosphate released upon 
nucleotide incorporation into the 
nascent DNA strand 
Nejentsev et al., 2009 
Taqman PCR  real-time PCR based 
high throughput genotyping 
technique  
Popa et al., 2009 
Genome Analyzer (GA) utilizes a form of ‘sequencing 
by-synthesis’ technology 
Gravina et al., 2013 
 
Table 1: DNA genotyping technologies from the origin to next generation  
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Drug Gene Function References 
Methotraxate ATIC 
SLC19A1 
GGH 
DHFR 
FPGS 
MTHFR 
SHMT1 
ABCB1 
IL1RN 
TYMS 
TGFβ1 
de novo purine synthesis 
transports folate and MTX into cell 
catalyzes the hydrolysis of folylpoly-gamma-glutamates 
reductase converting dihydrofolate into tetrahydrofolate 
maintains cytosolic and mitohondrial folylpolyglutamate  
generation of 5-methyl tetrahydrofolate 
generation of 5,10 methylene tetrahydrofolate 
efflux pump 
blocks induction of inflammation by IL-1 
de novo pyrimidine synthesis 
B cells inhibitor 
Owen et al., 2012 
Owen et al., 2012 
Owen et al., 2012 
Salazar et al., 2014 
Owen et al., 2012 
Berkun et al., 2004 
Davila and Ranganathan 2011 
Pawlik et al., 2004 
Tolusso et al., 2006 
Kumagai et al., 2003 
Daien et al., 2012 
Leflunomide DHODH 
C19A 
ESR1 
CYP1A2 
de novo pyrimidine synthesis 
unknown 
estrogen receptor 
cytochrome P450 
Powlik et al., 2004 
Davila and Ranganathan 2011 
Dziedziejko et al., 2010 
Bohanec et al., 2008 
Tocilizumab DHFR 
CCDC32 
EPHA 
TRAV8   
reductase converting dihydrofolate into tetrahydrofolate 
unknown 
ephrin receptor mediating cell-cell interactions 
T cell receptor 
Kurko et al., 2013 
Kurko et al., 2013 
Kurko et al., 2013 
Kurko et al., 2013 
Anti-TNFs HLA-DRB1  
PTPRC 
PTPN22 
AFF3 
CD226 
PDE3A–SLCO1C1  
PLA2G4A 
NUBPL 
CNTN5 
VAV1 
SPRED2 
PDZD2 
EYA4 
CENTD1 
MAFB2 
QK1 
LASS6 
IFNK 
CST5 
GBP6 
PON1 
LMO4 
MOBKL2B  
C9orf72 
DBC1 
FOXP1 
MAPK1 
MAPK14 
TNFRSF1B 
TANK 
TNF-alpha 
CHUK 
IRAK-3 
PTGS2 
TLR-2 
TLR-10 
MAPKAPK2 
MAP2K6 
shared epitope, HLA gene 
regulates BCR and TCR signaling 
Negative regulator of T cell activation 
transcription factor for lemphoid development 
type 1 membrane protein 
phosphodiesterase / cell membrane protein 
phospholipase for eicosanoids generation 
assembly of the NADH dehydrogenase 
member of immunoglobulin superfamily  
T cells protection from apoptosis  
regulator of growth factor-induced activation 
involved in intracellular signaling 
formation of axon connections 
T cells protection from apoptosis 
Regulator of T cell development and function 
RNA-binding protein 
influences insulin secretion 
co-transcription factor 
cysteine protease inhibitor 
hydrolyzes GTP to both GDP and GMP 
hydrolyzes organophosphate pesticides and nerve gasses 
transcriptional regulator 
spindle pole body duplication 
membrane trafficking regulation 
unknown 
regulates tissue- and cell type-specific gene transcription 
serine/threonine kinase of signal transduction pathway 
production of proinflammatory cytokines and MMPs 
TNF-receptor 
NF-kappa-B activator 
cell signaling protein involved in systemic inflammation 
regulates the NF-κB transcription factor 
Toll/IL-R immune signal transduction 
key enzyme in prostaglandin biosynthesis 
membrane protein involved in immune system 
pathogen recognition and activation of innate immunity 
involved in stress and inflammatory responses 
phosphorylation and activation of  p38 MAP kinase 
Potter et al., 2009 
Qui et al 2010 
Potter et al., 2009 
Tan et al., 2010 
Tan et al., 2010 
Acosta-Colman et al., 2013 
Mirkov et al., 2013 
Mirkov et al., 2013 
MIrkov et al., 2013 
Mirkov et al., 2013 
Mirkov et al., 2013 
Plant et al., 2011 
Plant et al., 2011 
Liu et al., 2008 
Liu et al., 2008 
Liu et al., 2008 
Liu et al., 2008 
Liu et al., 2008 
Liu et al., 2008 
Liu et al., 2008 
Liu et al., 2008 
Liu et al., 2008 
Liu et al., 2008 
Liu et al., 2008 
Krintel et al 2012 
Krintel et al 2012 
Bowes et al., 2009 
Coulthard et al., 2011 
Bowes et al., 2009 
Bowes et al., 2009 
O’Rielly et al., 2009 
Potter et al., 2010 
Potter et al., 2010 
Potter et al., 2010 
Potter et al., 2010 
Potter et al., 2010 
Coulthard et al., 2011 
Coulthard et al., 2011 
Rituximab TGFβ1 
FCGR3A 
BAFF 
B cells and immunoglobulin secretion inhibitor 
receptor for IgG 
activation factor of TNF 
Daien et al., 2012 
Kastbom et al., 2012 
Ruyssen-Witrand et al., 2012 
Sulfasalazine NAT-2 acetylation of sulfapyridine Tanaka et al., 2002 
------------------------------------------------------------------------------------------------------- 
 
Table 2: Overview of the drugs used for the treatment of Rheumatoid Arthritis, the 
genes involved in the Pharmacogenomics of these drugs, their function and pertinent 
references. 
 
